Building the healthcare business
First written in FY2016. 19 of 25 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-11-05.
No other company in this theme has enough history to compare yet.
- 2026-11-05AdvancedEarnings presentation
「2025年10月に医療機器製造販売承認を取得し、インフルエンザワクチン向けに発売。販売エリアの拡大や臨床データの取得を進め、使用実績の蓄積と新たな用途開発により事業拡大を図る。」
針なし注入器について、製造販売承認取得後の発売、販売エリア拡大、臨床データ取得および用途開発の段階を示した。 - FY2026AdvancedAnnual report
「In October 2025, Daicel Medical Co., Ltd., a Group company, obtained marketing approval for the Daicel Injector P1 SC, a gas-powered needle-free injector for pharmaceuticals and vaccines.」
In the healthcare business, our One Time Energy-based needle-free injector obtained marketing approval as a medical device, advancing to the stage of preparing for manufacturing and marketing. - FY2025AdvancedAnnual report
「In fiscal 2024, we launched BELLOCEA® BS7, a microparticle combining high biodegradability capable of addressing the microplastics regulations proposed by ECHA (the European Chemicals Agency) with a pleasant feel. We also launched two grades of a surfactant for cleansing formulations, P-PGLE MO04/MO06 (polyglyceryl oleate), manufactured using our proprietary technology.」
In the healthcare business, we launched BELLOCEA BS7, designed to address microplastics regulations, and two grades of surfactants for cleansing formulations. - FY2024AdvancedAnnual report
「For development of the novel drug-delivery device known as One Time Energy®, projects in Japan, the United States and Europe aimed at moving pharmaceuticals into clinical trials are under way, along with evaluation and joint experiments using our device with several major domestic and overseas pharmaceutical companies and venture companies.」
In the healthcare business, projects in Japan, the United States and Europe aimed at moving the novel drug-delivery device into clinical trials, as well as evaluation and joint experiments with multiple pharmaceutical and venture companies, are progressing. - FY2024-Q1AdvancedAnnual report
「In April 2023, the company established the Life Science SBU. The Life Science Business Planning Office had previously formulated and advanced business and R&D strategies for the Group’s healthcare-related businesses and prepared for the transition to an SBU. As the direction and business strategy of the business became clear, it was transitioned to the Life Science SBU. The SBU includes the Pharma-Tech BU, which integrates the former CPI Company and Formulation Solutions Business, including a service business focused on India that originated from the chiral column business and the concentration of resources in the genomics and genetics fields, and the Medical Business Development Department, which is working to establish the business foundation for bringing new drug-delivery devices into practical use as a medical-device business. Each initiative will be advanced efficiently.」
In the medical and healthcare businesses, we consolidated the healthcare-related businesses into the Life Sciences SBU and established a Pharmatech BU and a Business Development Department for novel drug-delivery devices. - FY2023AdvancedAnnual report
「The novel drug-delivery device known as One Time Energy®, based on energy control, officially went on sale in Japan as a scientific instrument in fiscal 2022.」
For the novel medical drug-delivery device, official sales began in Japan as a scientific instrument, advancing the business toward commercialization. - FY2023-Q1AdvancedAnnual report
「We will integrate the Daicel Group's healthcare-related businesses, including chiral columns, novel drug-delivery devices and formulation solutions, formulate and implement their business and R&D strategies, pursue synergies among the Group's healthcare-related businesses by leveraging the customer base of our chiral columns, which have the world's No. 1 market share, and accelerate R&D in areas such as gene therapy, where the Daicel Group's products and technologies can demonstrate their strengths.」
In the healthcare-related business, we established the Life Sciences Business Planning Office to integrate chiral columns, novel drug-delivery devices and formulation solutions, moving to an organizational structure designed to accelerate business synergies and R&D in gene therapy. - FY2022WorsenedAnnual report
「In the medical and healthcare businesses, we determined that sufficient future cash-flow recovery commensurate with the invested capital could no longer be expected and recognized impairment losses on property, plant and equipment and goodwill. The impairment loss recognized during the current fiscal year was ¥9,791 million.」
In the medical and healthcare businesses, impairment losses on property, plant and equipment and goodwill, based on the determination that recovery of invested capital had become less likely, totaled ¥9,791 million for the year. - FY2022-Q3WorsenedAnnual report
「In the medical and healthcare businesses, we determined that sufficient future cash-flow recovery commensurate with the invested capital could no longer be expected and recognized impairment losses on property, plant and equipment and goodwill. The impairment loss recognized during the nine-month period ended in the third quarter of the current fiscal year was ¥9,779 million.」
Although revenue and operating profit increased in the medical and healthcare businesses, we determined that cash-flow recovery commensurate with the invested capital could not be expected and recognized impairment losses of ¥9,779 million on property, plant and equipment and goodwill. - FY2021AdvancedAnnual report
「We developed “BELLOCEA®” (ベルロセア), spherical microparticles of cellulose acetate, and began sales in December 2020.」
In the healthcare business, we began selling BELLOCEA, a sustainable material for the cosmetics market, and advanced to the commercialization stage for a new product. - FY2021-Q3AdvancedAnnual report
「In December 2020, vaccination began for enrolled subjects, healthy adults, in the “Phase I/II Clinical Trial of a COVID-19 DNA Vaccine” conducted by Osaka University Hospital, a physician-initiated clinical trial, using our new drug-delivery device.」
In the healthcare business, administration to healthy adults began in clinical trials of a COVID-19 DNA vaccine using Actranza technology, marking progress into the clinical development stage. - FY2020AdvancedAnnual report
「Through the joint development by Osaka University and AnGes,Inc. of DNA vaccines using our novel drug-delivery device, the acceleration of DNA vaccine development, and manufacturing by TAKARA BIO INC., which has plasmid DNA manufacturing technology and facilities, we aim to begin clinical trials as soon as possible through an integrated process from development through manufacturing.」
In the healthcare business, we expanded into collaboration on the development and manufacture of DNA vaccines using Actranza™ Lab. - FY2020-Q3Cited as achievedAnnual report
「The Other segment reported higher revenue, partly because the overseas pharmaceutical formulation business acquired in the previous fiscal year contributed to results.」
This demonstrates that the acquisition of an overseas pharmaceutical formulation company contributed to higher revenue in the current quarter. - FY2020-Q1AdvancedAnnual report
「The Other segment reported higher revenue, partly because the overseas pharmaceutical formulation business acquired in the previous fiscal year contributed to results.」
This states that, following the acquisition of an overseas pharmaceutical formulation company, the formulation business contributed to higher revenue in the current quarter. - FY2019AdvancedAnnual report
「On 29 January 2019, we began providing Actranza™ Lab, a jet injector that we developed independently by applying our pyrotechnic engineering technology. We will work to realize a new drug administration method, or drug delivery system (DDS), that can lead to innovative pharmaceuticals such as gene therapy drugs, nucleic acid medicines and DNA vaccines.」
In the healthcare business, the launch of our drug-delivery device has made new business development for applications including gene therapy more concrete. - FY2019-Q3RestatedAnnual report
「Effective 1 August 2018, we acquired Lomapharm, a German contract pharmaceutical development and manufacturing company comprising LOMA Holding GmbH, Lomapharm Rudolf Lohmann GmbH KG and Lomapharm Verwaltungs GmbH. Going forward, we will work closely with Lomapharm to accelerate growth in the medical field, which we have positioned as one of the pillars of our new business areas.」
We continue to pursue a policy of accelerating growth in the medical field in collaboration with Lomapharm. - FY2019-Q2AdvancedAnnual report
「Effective 1 August 2018, we acquired Lomapharm, a German contract pharmaceutical development and manufacturing company comprising LOMA Holding GmbH, Lomapharm Rudolf Lohmann GmbH KG and Lomapharm Verwaltungs GmbH. Going forward, we will work closely with Lomapharm to accelerate growth in the medical field, which we have positioned as one of the pillars of our new business areas.」
In the healthcare business, we completed the acquisition of Lomapharm, a contract pharmaceutical development and manufacturing company, and advanced to the stage of accelerating growth in the medical field as a core area of our new businesses. - FY2018AdvancedAnnual report
「We are pursuing the commercialization of functional materials, including functional films, optical materials, pharmaceutical excipients and functional food ingredients, for which market and customer development has progressed.」
This indicates that functional materials, including pharmaceutical excipients and functional food ingredients for healthcare applications, have reached the commercialization stage. - FY2018-Q3RestatedAnnual report
「On 1 July 2017, we also invested in Wellness Open Living Lab LLC (abbreviated as WOLL).」
We continue to pursue the development of new research fields and solutions aimed at extending healthy life expectancy through our investment in WOLL. - FY2018-Q2AdvancedAnnual report
「From 1 July 2017, the company also acquired an equity interest in Wellness Open Living Lab LLC (abbreviated as WOLL). WOLL was established to address health-science issues, including dementia, with the aim of extending healthy life expectancy. It seeks to contribute to a range of activities, including providing products and services through the development of new research fields and promoting health through the use of data. Through its participation in these initiatives, the company will accelerate the development and provision of solutions that contribute to extending people’s healthy life expectancy.」
Participation in WOLL, which aims to extend healthy life expectancy, has made our involvement in new research fields and solution development related to health science more concrete. - FY2017-Q3AdvancedAnnual report
「The company is also developing functional food ingredients that contribute to health and beauty. Through joint research with Hokkaido University and the Hokkaido Research Organization, it elucidated the mechanism by which glucosylceramide, the active component of konjac ceramide, a raw material used in the company’s functional foods, is effective in alleviating hypersensitivity of itch-sensing nerves in the skin.」
Through joint research with Hokkaido University and others, the company elucidated the mechanism of action of the active component of konjac ceramide, advancing healthcare-related research toward concrete results. - FY2017-Q1AdvancedAnnual report
「As one of the new business units set out in its long-term vision, “Grand Vision 2020,” the company is pursuing product development and market development in the medical and healthcare fields. To create unique technologies based on these efforts and significantly expand its business in the medical field, the company decided to pursue new business creation through industry-academia collaboration. Accordingly, on 1 April 2016, it established the Medical Business Strategy Office within the Research and Development Division and the Future Medical Research Center in Suita, linked to the joint research course in “High-Speed Energy Therapy” with the Graduate School of Medicine, Osaka University.」
In the healthcare business, in addition to continuing product development and market development, the company established the Medical Business Strategy Office and the Future Medical Research Center, creating a commercialization structure through industry-academia collaboration. - FY2016First statedAnnual report
「On 1 April 2015, to accelerate the development of the healthcare business, the company acquired the Life and Health Business of UNITIKA LTD. and established the Healthcare Business Division within the Research and Development Division.」
The company is advancing entry into and commercialization in the medical and healthcare fields by acquiring the Life and Health Business and establishing a specialized division.